Managers / Q3 2024 · view latest →
Nebula Research & Development LLC
CIK 0001792635 · 225 5TH AVE, 10L, NEW YORK, NY, 10010 · 6465471243
Summary
Nebula Research & Development LLC reported $836M in U.S.-listed holdings across 901 positions for Q3 2024.
Compared with Q2 2024, the fund opened 442 new positions and exited 320.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 91.6% · $766M
- REIT · 5.7% · $47M
- Other · 2.6% · $22M
- Tracking Stk · 0.1% · $1M
- Closed-End Fund · 0.0% · $72,501
Quarter-over-Quarter Changes full breakdown →
vs Q2 2024 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| MSFTMICROSOFT CORP | NEW | +8.8K | 8.8K | +$4M | $4M |
| ALLALLSTATE CORP | NEW | +19.8K | 19.8K | +$4M | $4M |
| VVISA INC | NEW | +13.6K | 13.6K | +$4M | $4M |
| TPRTAPESTRY INC | NEW | +79.7K | 79.7K | +$4M | $4M |
| REGNREGENERON PHARMACEUTICALS | NEW | +3.6K | 3.6K | +$4M | $4M |
| LRNSTRIDE INC | NEW | +43.9K | 43.9K | +$4M | $4M |
| BMRNBIOMARIN PHARMACEUTICAL INC | NEW | +52.7K | 52.7K | +$4M | $4M |
| DTEDTE ENERGY CO | NEW | +27.7K | 27.7K | +$4M | $4M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q3 2024
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $0 | 1 | May 15, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $0 | 1 | Feb 13, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $0 | 1 | Nov 21, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $1.2B | 935 | Aug 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $1.1B | 925 | May 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $852M | 870 | Feb 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $836M | 901 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $618M | 779 | Aug 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $464M | 703 | May 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $332M | 619 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $190M | 473 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $132M | 324 | Aug 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $57M | 220 | May 15, 2023 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.